Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, December 9 at 2:00 PM ET

Register Free →

This Presolicitation opportunity from Government of Canada was posted on October 4, 2024. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Seeking Expression of Interest in Obtaining Canadian Licensure for Transdermal Scopolamine Patch

Closed
W6369-24-A013International

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 325412
New
Federal
6505--VA Loma Linda FDG
Solicitation # 36C26227Q0133
The Department of Veterans Affairs Loma Linda Healthcare System is conducting a Sources Sought and Request for Information (RFI) to identify qualified sources for a future single-award, Firm Fixed-Price Indefinite Delivery Indefinite Quantity (IDIQ) contract. The scope of work involves the procurement of radiopharmaceutical supplies, specifically 18-FDG, F18 NaF, and Bulk F-18 FDG. The intended period of performance consists of a base year starting December 15, 2026, followed by four option years ending December 14, 2031. The government is seeking providers capable of delivering sterile doses for intravenous injection that are compatible with the NMIS System and meet strict quality standards, including a radioactivity variance no greater than plus or minus 20 percent at the time of calibration. Deliveries will be made to the Nuclear Medicine Section at the Loma Linda facility, with routine orders required by the next business day and emergency orders required on the same day. The contractor must be licensed by the State of Operation and the Nuclear Regulatory Commission or an Agreement State Agency, and delivery personnel must be trained in Department of Transportation requirements and radiation safety. Interested parties must submit a capabilities statement, business size representations under NAICS 325412, and SAM.gov entity information to [email hidden] by November 20, 2026. This notice is for planning purposes only and does not constitute a formal solicitation.
262-NETWORK Contract Office 22 (36C262)

POSTED

1 day ago

DEADLINE

in 6 days

AI Contract Overview

Show more

The Department of National Defence and the Canadian Armed Forces are seeking expressions of interest from providers willing to obtain Canadian regulatory approval and licensure for an extended-release transdermal scopolamine patch. The product is intended for use during operations, exercises, and taskings to prevent nausea and vomiting associated with motion sickness, as there is currently no marketed version of this patch available in Canada. To enter the Canadian market, the product must be regulated as a Natural Health Product, requiring a Class III product license application and a site license for manufacturing, packaging, labeling, or importing. The product license application typically has a review period of 210 calendar days, while site license applications generally take between 30 and 90 days, with no current costs associated with these reviews. This presolicitation notice, identified by solicitation number W6369-24-A013, is an inquiry to determine industry interest and does not constitute a commitment to issue a formal request for proposals or incur costs.

General Info

DND seeks providers to obtain Canadian regulatory approval for transdermal scopolamine motion sickness patches.

Documents

1
PDF, Low priorityletter-of-interest
Low

AI Contract Breakdown

Uniform Contract Format

Contract not broken down yet

CLEATUS splits the solicitation into Uniform Contract Format (UCF) sections: scope, pricing, deliverables, and evaluation criteria.

Timeline

PhaseClosed
Posted

Solicitation

Response Deadline

Deadline has passed

Submission Closed

Find active opportunities like this

Get full access to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

Show more
AgencyGovernment of Canada → Department of National Defence
Contacts1 person available
OfficeN/A

Full Description

Show more
Letter of Interest Subject: Seeking Expression of Interest in Obtaining Canadian Licensure for Transdermal Scopolamine Patch The Department of National Defence (DND)/Canadian Armed Forces (CAF) is interested in obtaining an extended-release transdermal scopolamine patch for use on CAF operations, exercises, taskings, etc., to prevent nausea and vomiting associated with motion sickness. There is no marketed extended-release transdermal scopolamine patch in Canada, therefore, I'm reaching out to you to determine your interest in seeking regulatory approval/licensure of your transdermal scopolamine patch in Canada. Scopolamine transdermal patches are regulated in Canada as Natural Health Products (NHPs), under the Natural Health Products Regulations (NHPR). To obtain an NHP license in Canada for a transdermal scopolamine product, a Class III NHP product license application (PLA) is required. The Natural Health Products Management of Applications Policy (NHP MAP) outlines the process applied by Health Canada to manage PLAs for NHPs submitted in accordance with the NHPR. The policy also outlines the responsibilities and expectations of NHP applicants throughout the application process. Currently, Class III applications have a performance standard of 210 calendar days for review, and there are no costs for the review or right to sell the product on the Canadian market. A site license is required to manufacture, package, label or import NHPs for sale in Canada and is required before commencing any of these activities. The Site Licensing Guidance Document outlines the way in which Site License Applications for NHPs are submitted in accordance with the NHPR. Links to supporting documents can be found at Site Licensing Forms and Instructions and Site Licensing Guidance Documents. Currently, site license applications and amendments have a 30-90 calendar day performance standard, and there are no costs associated with the license.

Find Active Opportunities Like This

Get AI-powered intelligence on the opportunities still open

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS